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Alzheimer’s disease (AD) is associated with pathological assembly states of amyloid- protein (A). A-related synaptotoxicity can be
blocked by anti-prion protein (PrP) antibodies, potentially allowing therapeutic targeting of this aspect of AD neuropathogenesis. Here,
we show that intravascular administration of a high-affinity humanized anti-PrP antibody to rats can prevent the plasticity-disrupting
effects inducedby exposure to solubleADbrain extract. These results provide an in vivoproof of principle for such a therapeutic strategy.
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Introduction
Alzheimer’s disease (AD) presents one of the greatest healthcare
and economic challenges globally, but no effective therapy to halt
or delay disease progression has been developed. Rather than
being a single disease entity, ADmay be considered a clinicopath-
ological syndromewithmultiple interacting genetic and environ-
mental factors involved in its onset and progression. Aggregation
of the amyloid- protein (A) is believed to be central, with
water-soluble nonfibrillar assemblies closely linked to memory
impairment (Benilova et al., 2012). Only certain synthetic and
cell-derived A preparations are synaptotoxic in vitro at patho-
physiologically pertinent low nanomolar concentrations (Beni-
lova et al., 2012). Importantly, soluble extract from AD brain
contains potent toxic A assemblies that can rapidly disrupt hip-
pocampal long-term potentiation (LTP; Shankar et al., 2008), a
form of synaptic plasticity implicated in memory and learning
(Bliss and Collingridge, 1993). Although different assembly
forms of A may exert toxicity by different mechanisms (Beni-
lova et al., 2012), it is known that prion protein (PrP) is required
for at least some aspects of A toxicity (Laure´n et al., 2009; Barry
et al., 2011; Freir et al., 2011). Targeting PrP, which has been
investigated extensively as a strategy for treating prion disease, is
attractive because both constitutive knock-out of PrP expression
and ablation of neuronal PrP expression in the adult mouse are
withoutmajor phenotypes (Nicoll andCollinge, 2009). Themurine
monoclonal antibodies 6D11 (Laure´n et al., 2009), Fab-D13 (Barry
et al., 2011), and ICSM35 (Freir et al., 2011), which bind directly to
the A-binding site on PrP (Laure´n et al., 2009), block A-
induced inhibition of LTP, as does ICSM18, which binds to
helix-1 of PrP (Freir et al., 2011). 6D11 was shown to reverse
behavioral deficits when administered intraperitoneally into an
amyloid precursor protein/presenilin-1 mutant mouse model of
AD (Chung et al., 2010), but it is uncertain whether this involved
a direct action in the nervous system or how the A assemblies in
transgenic mouse models relate to those found in human AD
brain. It has been suggested that cross-linking of PrP by antibod-
ies that interact close to the A-binding site on PrP triggers neu-
ronal apoptosis in vivo (Solforosi et al., 2004), although we were
unable to confirm this (Klohn et al., 2012). Furthermore, cross-
linking via this epitope of PrP has been proposed as a cause of
PrP-dependent A toxicity (Bate and Williams, 2011) and this
region has been suggested to be involved with PrP function and
binding interactions (Be´land and Roucou, 2012). In contrast,
antibodies that bind to only helix-1 of PrP are consistently innoc-
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uous, even on direct injection into the hippocampus at 1 mg/ml
(Solforosi et al., 2004; Klohn et al., 2012; Ohsawa et al., 2013),
which produces a local concentration of up to 6 M—10,000-
fold higher than the dissociation constant (Antonyuk et al.,
2009). Because clinical therapeutic use would preferentially in-
volve dosing of antibody via intravenous or subcutaneous routes,
we sought to determine whether peripheral administration of a
humanized anti-PrP antibody could effectively target PrP-A in-
teractions and prevent the disruptive effects of toxic AD brain A
assemblies in vivo (Roettger et al., 2013).
Materials andMethods
Antibody development. Antibody humanization was performed with the
complementarity-determining region grafting method (Jones et al.,
1986) and human frameworks were chosen on the basis of their conser-
vation of key framework residues (Williams et al., 2010). Candidate hu-
manized antibodies were then expressed as IgG1molecules and retention
of binding to antigen was confirmed by ELISA. The lead candidate was
cloned in an IgG4 format selected for reduced effector function before
progressing to cell line development using a proprietary glutamine syn-
thetase expression system (Lonza Biologics). The construct encodes a Ser
to Pro mutation at the interheavy chain disulfide bond to strengthen the
hinge region and reduce the formation of half antibody (Angal et al.,
1993). PRN100 was manufactured from themaster cell bank at the 200 L
scale and purified using a two-step chromatography process to generate
highly purified antibody (99.3% by HPLC).
Immunoprecipitation and Western blotting of PrP from normal human
brains. Human brain samples were obtained and used under ethical ap-
proval from theNational Research Ethics Service (03/133), homogenized
to 10% w/v in Dulbecco’s Mg2/Ca2-free PBS (Invitrogen) with a
Dounce homogenizer, and used for immunoprecipitation and Western
blotting, as described previously (Khalili-Shirazi et al., 2005), with
ICSM18 (D-Gen) as the detection antibody.
Protein expression and purification. Constructs of human PrP were
expressed (Jackson et al., 1999) and purified (Zahn et al., 1997) as de-
scribed previously. Protein quality was confirmed by SDS-PAGE,
MALDI-TOF mass spectrometry, and circular dichroism spectroscopy.
Antibody affinity ELISA. ELISA plates were coated with recombinant
murine PrP91-231 (2.5g/ml) in 50mM sodium carbonate buffer, pH 9.6,
washed with PBS (0.05% Tween 20), and blocked with Superblock T20
(Thermo Scientific). PRN100 or ICSM18 diluted in PBS (0.1% bovine 
globulin) were incubated andwashedwith PBS (0.05%Tween 20) before
detecting with species-specific HRP conjugated antibodies (Sigma) in
PBST (0.05% Tween 20) coupled to a 3,3,5,5-tetramethylbenzidine
(BD Biosciences) substrate. Absorbance at 450
nm was read using a Tecan Sunrise plate.
Preparation of human AD brain extract for
electrophysiology. Brain was prepared as de-
scribed previously (Freir et al., 2011). Brain tis-
sue froma 92-year-oldwomanwith a history of
dementia and confirmed AD pathology was
obtained and used in accordance with local In-
stitutional Review Board guidelines. Human
temporal cortex was homogenized in 1:5 (w/v)
ice-cold Tris-buffered saline (TBS), pH 7.4,
containing protease inhibitors with 20 passes
of a Dounce homogenizer (Fisher Scientific).
The homogenized samples were centrifuged at
175,000  g for 30 min at 4°C and the super-
natant (TBS extract) was removed. TBS extract
was desalted and A-rich fractions were
pooled and the A content estimated using a
sensitive immunoprecipitation/Western blot
protocol. Known amounts of synthetic A1-42
were electrophoresed on the same gel to allow
quantification of A in the TBS extract. After
transfer, membranes were immunoblotted
with a combination of the monoclonal anti-
bodies 2G3 and 21F12 (1:1000 dilution). Goat anti-mouse antibody (1:
2500 dilution) conjugated to infrared dye was used to visualize A bands
using a LI-COR Odyssey Near Infrared Imaging system.
Electrophysiology. In vivo electrophysiology was performed as de-
scribed previously (Klyubin et al., 2008; Freir et al., 2011). Animal exper-
iments were licensed by theDepartment ofHealth andChildren, Ireland.
AdultmaleWistar ratswereanesthetizedwithurethane(1.5g/kg, i.p.). Single
pathway recordings of field EPSPs weremade from the stratum radiatum in
the CA1 area of the dorsal hippocampus in response to stimulation of the
ipsilateral Schaffer collateral/commissural pathways. Test EPSPs were
evoked at a frequency of 0.033 Hz and at a stimulation intensity adjusted to
give an EPSP amplitude of 50% ofmaximum. The high-frequency stimula-
tion (HFS) protocol for inducing LTP consisted of 10 trains of 20 stimuli,
interstimulus interval of 5ms, and an intertrain interval of 2 s. The intensity
was increased to give an EPSP of 75% of maximum amplitude during the
HFS. LTP is expressed as themean SEMpercentage of baseline field EPSP
amplitude recorded over at least a 30 min baseline period. Similar results
were obtained when EPSP slope rather than amplitude was measured.
For statistical analysis, EPSP amplitudes were grouped into 10 min
epochs. Standard one-way ANOVA was used to compare the magnitude
of LTP between multiple groups, followed by post hoc Tukey’s tests.
Unpaired Student’s t tests were used for two-group comparisons. p 
0.05 was considered statistically significant.
To inject samples into the rat brain, a cannula was implanted in the
lateral cerebral ventricle (coordinates: 1 mm lateral to the midline and 4
mm below the surface of the dura) just before electrode implantation.
Injections (10–8 l over 6–8 min) were made via a Hamilton syringe
connected to the internal cannula. Control human myeloma IgG4 
antibody was obtained from Sigma (catalog #I4639). An interval of 1.5 h
or more was left between the implantation procedure and the intracar-
diac injection of 0.6 ml of PRN100 or buffer (25 mMNaAc, 75 mMNaCl,
pH5.5) under urethane anesthesia. Intracardiac injectionsweremade via
a 23 ga needle inserted directly into rat heart.
Histology and imaging. Brains were fixed in 10% buffered formal sa-
line, immersed in 98% formic acid for 1 h, and paraffin wax embedded
after formalin postfixation. Sections of 4 m nominal thickness were
stained with H&E to visualize basic structures and immunostained for
additional markers (microglia: Iba-1 antibody, Wako; myelinated fiber
tracts: SMI-94R, Covance; cleaved Caspase-3: Asp175, Cell Signaling
Technology) on Ventana Discovery XT automated biomarker platforms
using EZ Prep Solution and antigen retrieval with Cell Conditioning
Solution Plus (Ventana). Immunostainings were visualized using the
DAB Map Detection Kit (Ventana). Sections were counterstained with
hematoxylin and coverslipped on a Leica CV5030 coverslipper. Slides
were digitized on a Leica SCN400 slide scanner, visualized on the Slide-
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Figure1. Thehumanizedmonoclonal antibodyPRN100displays similar PrP-bindingproperties to itsmurineparent, ICSM18.A,
Both ICSM18 and PRN100 efficiently immunoprecipitate all major PrP glycoforms from human brain homogenate.B, Representa-
tive binding isotherm of PRN100 (blue) and ICSM18 (orange) show a similar high-affinity interaction to surface-bound recombi-
nant murine PrP91-231.
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Path Digital Image Hub. Regions of interest were captured with a screen
capture tool, followed by arranging captures in Adobe Photoshop.
Collection of plasma and CSF. A cisternal puncture method was used
for CSF sampling under anesthesia. After exposing the atlanto-occipital
membrane, CSFwas collected from the cisternamagna.Whole bloodwas
obtained from the anesthetized animal by decapitation, collected into
Eppendorf tubes containing30 l of 0.5 M EDTA, and inverted several
times before being centrifuged for 10 min at 1000 g. Plasma and CSF
were stored frozen at80°C.
PRN100 detection ELISA. ELISA plates were coated with recombinant
murine PrP91-231 (2.5g/ml) in 50mM sodium carbonate buffer, pH 9.6,
washed with PBS (0.05% Tween 20), and blocked with Superblock T20
(ThermoScientific). Sera (1:2000) andCSF (1:5) diluted in PBS (2%milk
powder) were incubated and washed with PBS (0.05% Tween 20) before
detecting with anti-human Fc-specific HRP conjugated antibody (1:
25,000) in PBST (0.05% Tween 20; Sigma) coupled to a 3,3,5,5-
tetramethylbenzidine (BD Biosciences) substrate. Absorbance at 450 nm
was read using a Tecan Sunrise plate reader with concentrations of
PRN100 calculated relative to purified standard curves diluted in equiv-
alent buffer and control fluid.
Evans blue assay. Anesthetized rats were infused with a 2% solution of
Evans blue (2 ml/kg, intracardiac). Five minutes after the treatment, the
animals were killed by intracardiac perfusion with PBS and brains were
harvested and preserved in formaldehyde.
Results
PRN100 retains key binding properties of ICMS18
As part of a program to develop a monoclonal anti-PrP antibody
for passive immunotherapy of prion infection and disease, we
have developed a fully humanized version of ICSM18, a high-
affinity mouse monoclonal antibody effective in treating murine
prion infection (White et al., 2003; Freir et al., 2011; Klohn et al.,
2012). An IgG4 isotype was engineered as a clinical candidate to
minimize unwanted Fc effector function and was designated
PRN100. Both ICSM18 andPRN100 recognized, and successfully
immunoprecipitated, all isoforms of PrP found in human brain
(Fig. 1A). This suggests that PRN100 has the potential to target
the same PrP species as ICSM18 in vivo and could block the
A-induced disruption of LTP caused by PrP-dependent assem-
blies. PRN100 bound avidly to high-density recombinantmurine
PrP with an apparent dissociation constant (50  10 pM) com-
parable to that (40 20 pM) for ICSM18 (Fig. 1B, n	 4). There-
fore, the efficacious dose of PRN100 should be similar to
ICSM18, but with reduced probability of Fc effector-related tox-
icity. These data indicate that PRN100 has retained key PrP-
binding properties of ICSM18.
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Figure2. PRN100blocks solubleADbrain (A) extract-induced inhibition of hippocampal LTP
when infused centrally (B) or peripherally (C). A, Soluble AD brain extract contained 3.8 ng/ml
Amonomers and 2.4 ng/ml A dimers asmeasured by sensitive immunoprecipitation/West-
ern blotting technique. Bandsmigrating at amolecularweight consistent for Amonomer (M)
and SDS-stable dimer (D) are seen in the AD TBS extract. Synthetic A1-42 standards loaded for
protein quantification are shownon the left. Nonspecific immunoreactive bands (NS)migrating

17 kDa can also be seen in the negative control lane (ve).B, Synaptic field potentials were
recorded in vivo from the CA1 area of anesthetized male Wistar rats. In buffer-injected rats
4
(1: first injection 10l, i.c.v.; 2: second injection 8l 30min later) HFS 15min after the second
injection triggered persistent and stable LTP (black diamonds, 169 17% at 3 h after tetanus,
n	 5). In contrast, significant inhibition of LTP was observed after injection of 8 l of A-
containing brain extract in animals preinjected with buffer (gray triangles, 103 5%, n	 5,
p0.05) or 30gof an IgG4 isotype control antibody (IgG4kappa, red circles, 1005%,n	
5, p 0.05). However, injection of PRN100 (30g) 30min before injection of soluble AD brain
extract prevented the inhibition of LTP (blue squares, 176 14%, n	 5). C, In buffer-injected
rats (1: first injection 600l, intracardiac; 2: second injection 8l, i.c.v. 30 min later) HFS 15
min after the second injection triggered persistent and stable LTP (black diamonds, 149 14%
at 3 h after tetanus, n	 6). Intracardiac injection of buffer followed by intracerebroventricular
infusion of AD brain fully inhibited LTP (red circles, 104 3%, n	 6, p 0.05). Intracardiac
injection of 6 mg of PRN100 reversed this effect (blue squares, 141 10%, n	 5), showing
that peripheral administration of PRN100 blocks AD brain extract-derived A synaptotoxicity.
The PRN100measurements were conducted blind (gray triangles vs blue squares). Insets show
representative EPSP traces. Top trace corresponds to 5 min before HFS and the bottom to 3 h
after HFS. Horizontal bar, 5 ms; vertical bar, 1 mV.
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Peripheral infusion of PRN100 blocks AD brain-induced
inhibition of LTP
We then tested whether PRN100 could prevent the synaptic
plasticity-disrupting action of soluble AD brain extract in live
rats, as we have described for ICSM18 (Freir et al., 2011). After
intracerebroventricular injection of buffer alone, a robust LTP
could be evoked using an HFS protocol. However, injection of a
water-soluble ADbrain extract rich inA species, including SDS-
stable dimers (Fig. 2A), fully inhibited LTP within 3 h (Fig. 2B).
Importantly, brain extract immunodepleted ofAdid not inhibit
LTP (n 	 5, data not shown). When 30 g of PRN100 was in-
jected 30 min before the AD brain extract, robust LTP was also
observed, indicating that PRN100 can block the disruptive effect
of A found in AD brain. An isotype control human IgG4 (IgG4
kappa purified from human myeloma plasma) failed to prevent
the toxic effect. Neuropathological analysis showed no signs of
PRN100-induced neuronal apoptosis, microglial activation, or
demyelination (Fig. 3).
For peripherally administered PRN100 to be therapeutically ac-
tive against either established neuroinvasive prion infection or
AD, it will need to cross the blood–brain barrier (BBB) and target
PrP in relevant regions of the brain such as the hippocampus
(Roettger et al., 2013). Pharmacokinetic studies are ongoing to
determine the dosing regime required to obtain therapeutic levels
in the CNS, which will require sufficient dosing to overcome
target-mediated drug disposition, because PrP is also widely ex-
pressed in the periphery (Linden et al., 2008).However, as a proof
of principle, we injected a single 6 mg dose of PRN100 via the
intracardiac route 1 h before intracerebroventricular injection of
AD brain extract and monitored the effect on LTP induction.
Remarkably, such intravascular infusion of PRN100 also pre-
vented inhibition of LTP, suggesting that PRN100 was able to
cross the BBB and target PrP (Fig. 2C). As with direct intracere-
broventricular injection, there was no histologically detectable
neurotoxicity (Fig. 4). We collected blood and CSF from the rats
used in the study and quantified PRN100 concentrations. ELISA
detection, performed in a blinded fashion, correctly identified all
rats with PRN100 in their blood and CSF. Concentrations of
1.4 0.7MPRN100 (210 110g/ml) were detected in serum
and 1.7 3.4 nM (0.26 0.51g/ml) concentrations were found
in CSF (equivalent to0.1% of that detected in blood), confirm-
ing that sufficient PRN100 can enter the CNS even after a single
dose (n 	 5) to achieve a pharmacodynamic effect. A non-BBB
penetrant dye, Evans blue (Kozler and
Pokorny´, 2003), was injected via the intra-
cardiac route 2 h after electrode implanta-
tion to test for BBB integrity and was not
detected at the electrode site or elsewhere
in the brain (data not shown).
Discussion
The potential for anti-PrP antibodies to
prevent A synaptotoxicity in AD has
been established previously. However, no
fully humanized anti-PrP antibody po-
tentially applicable to AD patients has
been reported. We show that PRN100 re-
tains key properties of the parent murine
antibody, ICSM18, and can block A-
induced inhibition of LTP when injected
directly into the brain without inducing
overt acute neurotoxicity. It would be in-
teresting to determine whether PRN100
can also reverse behavioral deficits seen in
AD rodent models, although maintaining long-term dosing may
be difficult if antidrug antibodies develop and the PrP depen-
dence of toxicity varies between models and at different time
points. Furthermore, it was unknown whether such antibodies
could cross the BBB in sufficient quantities to target PrP in
disease-relevant areas of the brain such as the hippocampus. We
have now shown that, after a single injection into the rat blood
stream, PRN100 can indeed reach therapeutically active concen-
trations even when subnanomolar concentrations are detected in
theCSF.We could not reliably visualize PRN100 in fixed rat brain
parenchyma using immunohistochemistry due to diffuse back-
ground staining. The concentrations observed in the CSF are well
below any reported toxic concentrations (Solforosi et al., 2004;
Sonati et al., 2013).
Recently, Sonati et al. (2013) have reported acute toxicity as-
sociated with some, but not other, anti-PrP antibodies from their
POM series (Polymenidou et al., 2008). Toxicity was observed
principally in organotypic slice cultures from, and limited in vivo
studies in, transgenic mice with high levels of PrP overexpression
(Sonati et al., 2013). There was an inconsistent association with
epitope. Toxicity was seen at very high local concentrations after
direct injection into brain parenchyma and is of questionable
relevance to any likely human therapeutic approach.
Although all therapeutics will be toxic at sufficiently high
acute or chronic dosing, formal safety studies have been per-
formed as part of the evaluation of PRN100 before an application
to UK regulators for a clinical trial authorization (in the primary
indication for which PRN100 was developed, Creutzfeldt-Jakob
disease [CJD]). Subject to an acceptable risk: benefit evaluation, it
is envisaged that first-in-human studies would be in patients with
sporadic CJD, a uniformly fatal condition with a mean clinical
duration of 4 months. A single ascending dose safety study has
been performed in cynomolgus macaques (Covance) to under-
pin this study and showed no clinical or pathological evidence of
CNS toxicity at intravenous doses up to and including 200mg/kg
(achieving peak serum concentrations in excess of 5mg/ml), well
in excess of those proposed for initial human studies.
Several fully penetrant inherited forms of prion disease are
caused by single amino acid substitutions in the A-binding
epitope and many are found throughout the C terminus of the
structured domain, but none are known in the helix-1 region
(Collinge, 2001). Therefore, using antibodies exclusively target-
Figure 3. ICV injection of PRN100 did not cause overt neuronal damage up to 4 h after administration. Shown is the immuno-
histochemical analysis of hippocampi from PRN100-injected (A–C) and isotype control-injected (D–F) rats. H&E or immunohisto-
chemical (Iba-1 or SMI-94) staining (A, D) shows no evident neuronal damage, demyelination (C, F), or microglial activation in
PRN-100 treated rats (B) compared with isotype control-treated animals (E). Scale bar, 100M.
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ing helix-1 of PrP may be a superior therapeutic strategy to re-
duce PrP-dependent A toxicity rather than using antibodies
with nonlinear epitopes or those that directly target the A bind-
ing site itself.
Should proposed clinical studies of PRN100 in prion disease
(a rapidly fatal, untreatable condition) demonstrate adequate
safety characteristics and pharmacokinetic parameters in hu-
mans, it may be appropriate to consider experimental medicine
studies in early AD to determine whether PRN100 administra-
tion has acute effects on memory and learning, which would
suggest a potential role for blocking PrP-A interactions in AD
therapeutics.
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